Dostarlimab
- Generic Name
- Dostarlimab
- Brand Names
- Jemperli
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2022215-59-2
- Unique Ingredient Identifier
- P0GVQ9A4S5
- Background
Dostarlimab is an IgG humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically att...
- Indication
Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.
...
- Associated Conditions
- Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer, Advanced Mismatch repair deficient (dMMR) solid tumors, Recurrent Microsatellite Instability (MSI)-High Endometrial Cancer, Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer, Recurrent Mismatch repair deficient (dMMR) solid tumors
- Associated Therapies
- -
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 340
- Registration Number
- NCT05565378
- Locations
- 🇬🇧
GSK Investigational Site, Wolverhampton, United Kingdom
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-11-29
- Target Recruit Count
- 25
- Registration Number
- NCT05526989
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- University of Miami
- Registration Number
- NCT05405192
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT05277051
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 25
- Registration Number
- NCT05239546
- Locations
- 🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 260
- Registration Number
- NCT05201547
- Locations
- 🇫🇷
CHU d'Amiens - Hôpital Sud, Amiens, France
🇫🇷Clinique de l'Europe, Amiens, France
🇫🇷CH Simone Veil de Beauvais, Beauvais, France
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
- Conditions
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT05126342
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 40
- Registration Number
- NCT05065021
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 153
- Registration Number
- NCT05060432
- Locations
- 🇧🇪
Cliniques universitaires St Luc-UCL, Brussels, Belgium
🇧🇪Jessa Ziekenhuis, Hasselt, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Joseph Caster, Ph.D., M.D.
- Target Recruit Count
- 38
- Registration Number
- NCT04926324
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.